Source-grounded facts extracted from Taysha Gene Therapies, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Taysha Gene Therapies, Inc. shareholders approved Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-06-01 meeting.
“Proposal No. 4 : Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 360,924 630,378 67,607 Broker Non-Votes: 38,973,186”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-01 meeting.
“Proposal No. 3 : Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 36,396,784 345,291 Broker Non-Votes: 38,973,186”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-01 meeting.
“Proposal No. 2 : Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 25,551 18,176 Broker Non-Votes: 0”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-01 meeting.
“Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 169,142,295 35,742,331 Laura Sepp-Lorenzino, Ph.D. 150,094,517 54,790,109 Broker Non-Votes: 38,973,186 Both nominees were elected.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 6, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2026, and recent business highlights.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for fiscal year ended December 31, 2025.
Taysha Gene Therapies, Inc.: Increase in authorized common stock from 400,000,000 to 700,000,000 (effective 2025-06-02).
“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Amendment ”) to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for Full Year 2023.
“On March 19, 2024, Taysha Gene Therapies, Inc. (the " Company ") reported financial results for the year ended December 31, 2023 and recent business and clinical updates.”
Governance Changes
Taysha Gene Therapies, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2023-11-15).
“On November 15, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the authorized number of shares of the Company’s common stock from 200,000,000 shares to 400,000,000 shares.”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Approval of an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. at the 2023-11-15 meeting.
“Proposal No. 1: Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company's common stock from 200,000,000 to 400,000,000. The votes were cast as follows: Votes For Votes Against Abstained Amendment to effectuate an authorized shares increase 133,386,292 1,370,285 157,132”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.”
Alison Long was appointed as Director at Taysha Gene Therapies, Inc..
“On October 30, 2023, the Board appointed Alison Long to serve as a director of the Company, effective immediately following Dr. Reape’s resignation (the “ Effective Time ”).”
Kathleen Reape resigned as Director at Taysha Gene Therapies, Inc..
“Kathleen Reape provided notice to the board of directors (the “ Board ”) of Taysha Gene Therapies, Inc. (the “C ompany ”) of her decision to resign from the Board and all committees thereof, effective November 1, 2023, in accordance with the governance guidelines of Dr. Reape’s employer and not as a result of any disagreement with the Company.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 14, 2023, the Company reported financial results and business highlights for the quarter ended June 30, 2023.”
Material Agreements
Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at approximately $150.0 million (effective 2023-08-14).
“On August 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional and other accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 122,412,376 shares (the “ Shares ”) of the Company’s common stock, par value $0.00001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 44,250,978 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.”
Listing & Compliance Notices
Taysha Gene Therapies, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).
“August 3, 2023, Taysha Gene Therapies, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock (the “Common Stock”), which continues to trade on The Nasdaq Global Select Market under the symbol “T”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Approval to adopt a series of alternate amendments to the Company's Certificate of Incorporation to effect an authorized shares reduction, with specific number of authorized shares determined by formula based on ratio utilized for reverse stock split at the 2023-06-22 meeting.
“Proposal No. 4: Approval to adopt a series of alternate amendments to the Company's Certificate of Incorporation to effect an authorized shares reduction, with the specific number of authorized shares determined by a formula that is based on the ratio utilized for a reverse stock split. The votes were cast as follows: Votes For Votes Against Abstained Amendment to effectuate an authorized shares reduction 43,305,340 10,246,833 190,654 Broker Non-Votes: 0.”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
“Proposal No. 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Deloitte & Touche LLP 53,532,998 51,055 158,774 Broker Non-Votes: 0.”
Shareholder Votes
Taysha Gene Therapies, Inc. shareholders approved Election of Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. as directors at the 2023-06-22 meeting.
“Proposal No. 1: Election of two nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 35,556,636 3,890,877 Laura Sepp-Lorenzino, Ph.D. 33,595,590 5,851,923 Broker Non-Votes: 14,295,314. Both nominees were elected.”
Sean Stalfort was appointed as director at Taysha Gene Therapies, Inc..
“on June 21, 2023, the Board appointed Sean Stalfort to serve as a director of the Company, effective immediately following Mr. Manning’s resignation”
Paul B. Manning resigned as director at Taysha Gene Therapies, Inc..
“on June 20, 2023, Paul B. Manning provided notice to the Board of his decision to resign from the Board and all committees thereof”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for quarter ended March 31, 2023.
“Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.”
Listing & Compliance Notices
Taysha Gene Therapies, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 25, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 23, 2023, to regain compliance with the minimum bid price requirement. To regai”
Kathleen Reape was appointed as Class I Director at Taysha Gene Therapies, Inc..
“Effective immediately prior to the conclusion of the 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”), the Company expects that Dr. Reape will resign as a Class III director of the Company. Upon her resignation, the Board intends to appoint Dr. Reape as a Class I director of the Company to serve until the 2024 annual meeting of stockholders.”
Kathleen Reape resigned as Director at Taysha Gene Therapies, Inc..
“Kathleen Reape provided notice to the board of directors (the “ Board ”) of the Company of her decision to resign from the Board, effective November 1, 2023.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2022.
“Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.”
R.A. Session II resigned as Director at Taysha Gene Therapies, Inc..
“On March 2, 2023, Mr. Session notified the Board of his resignation from the Board and all committees thereof effective immediately.”
R.A. Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..
“On December 16, 2022 (the “ Separation Date ”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately.”
Suyash Prasad departed as Chief Medical Officer at Taysha Gene Therapies, Inc..
“On January 12, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) and Suyash Prasad, the Company’s Chief Medical Officer, mutually agreed to Dr. Prasad’s separation from the Company, effective immediately.”
Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..
“the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective December 16, 2022.”
Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..
“the Company’s board of directors (the “ Board ”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022.”
Suyash Prasad changed role as Chief Medical Officer at Taysha Gene Therapies, Inc..
“Dr. Suyash Prasad’s title was changed from Chief Medical Officer and Head of Research and Development to Chief Medical Officer, effective as of Dr. Nagendran’s appointment.”
Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..
“On December 16, 2022, the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective immediately.”
Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..
“On December 16, 2022, the Board appointed Sean Nolan as the Company’s Chief Executive Officer, effective as of the effective time of Mr. Session’s resignation.”
RA Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..
“On December 16, 2022, RA Session II, the President and Chief Executive Officer of Taysha Gene Therapies, Inc. (the “ Company ”), resigned from his operating role, effective immediately.”
Earnings Releases
Taysha Gene Therapies, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 8, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter and nine months ended September 30, 2022.”
Material Agreements
Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas") valued at approximately $30.0 million (effective 2022-10-21).
“On October 21, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Astellas, pursuant to which the Company agreed to issue and sell to Astellas in a private placement (the “Private Placement”) an aggregate of 7,266,342 shares”
Material Agreements
Taysha Gene Therapies, Inc. entered into Option Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas") valued at $20.0 million (effective 2022-10-21).
“On October 21, 2022 (the “Effective Date”), Taysha Gene Therapies, Inc. (the “Company”) entered into an Option Agreement (the “Option Agreement”) with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (“Astellas”).”
Material Agreements
Taysha Gene Therapies, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC (effective 2022-10-26).
“On October 26, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC (the “ Underwriter ”), to issue and sell 14,000,000 shares of common stock of the Company, par value $0.00001 per share (“ Common Stock ”), in an underwritten public offering pursuant to effective registration statements on Form S-3 (File No. 333-260069) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “ Offering ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.